

CIRM Funded Clinical Trials

Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial.

Disease Area:	Melanoma
Investigator:	Robert Dillman
Institution:	Caladrius Biosciences
CIRM Grant:	CLIN2-08239 (Closed)
Award Value:	\$3,000,000
Trial Sponsor:	Caladrius Biosciences
Trial Stage:	Phase 3
Trial Status:	Closed
Targeted Enrollment:	4
ClinicalTrials.gov ID:	NCT01875653



Robert Dillman

Details:

NeoStem, which later changed its name to Caladrius BioScience, ran a Phase 3 trial targeting cancer stem cells. These cells are believed to be able to survive chemotherapy and other cancer-targeting treatments, and can cause a relapse by enabling tumors to grow and spread. This approach used the patient's own tumor cells to create a personalized therapy, one designed to engage the patient's own immune system and destroy the cancer. The trial was halted by Caladrius in January 2016 for business reasons.

Source URL: <https://www.cirm.ca.gov/clinical-trial/tumor-stem-cell-targeted-immunotherapy-metastatic-melanoma-%E2%80%93-randomized-phase-3>